The intellectual property landscape for urolithin A
A complex international landscape
Using urolithin A as an ingredient means navigating a complex international IP environment: core efficacy, compositions and dosage forms are patented in the major markets, and enforcement is active. In October 2025 the originator sued 30 online sellers in U.S. federal court; in July 2026 it obtained permanent injunctions against 19 of them and a combined USD 5.3 million in damages, with the largest single award above USD 2.7 million and treble damages applied in some cases.
Directions already under patent protection
Based on continuous patent searching and analysis, the following directions are covered by third-party patents and may not be used in your product claims or formulations without authorisation: the mitophagy mechanism and its efficacy claims (muscle function · anti-ageing), skin compositions combining urolithin A with NAD precursors, sensitive-skin and anti-hair-loss applications, SIRT6 activation, and several routes that promote in-vivo production through precursors or probiotics. Continuously updated patent analysis is provided in the biweekly brief.
Process freedom-to-operate assessment complete
A freedom-to-operate search and assessment of the current manufacturing process has been completed. Qualified partners may review it under NDA.
Taiyi Health's own patents
TI-3N® three-component composition (urolithin A + fisetin + ergothioneine): PCT international search completed, U.S. national phase in progress; proprietary efficacy and pathway patents pending.
Biweekly patent analysis
Taiyi Health's Science Department, working with a U.S. law firm, reviews and summarises patent activity every two weeks in the
UA Patent Biweekly.
Request the biweekly
This website does not provide legal advice, does not disclose the contents of FTO documents, and expresses no opinion on the validity or scope of any third-party patent; please rely on your own counsel for compliance decisions.
The UA Patent Biweekly
Every two weeks our patent analysis team reads the latest patent activity in the urolithin A field and writes a report that procurement and legal teams can both use, reviewed by our legal team before release. Subscription is free.